ArcherDX Growth, Revenue, Number of Employees and Funding

Overview

Location:
Boulder, CO USA
Total Funding:$95M
Industry:Biotech
Founded:2013
Lead Investor(s):Boulder Ventures, PBM Capital Group, LLC
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • ArcherDX's estimated revenue is currently $33.3M per year.
  • ArcherDX received $35.0M in venture funding in March 2018.
  • ArcherDX's estimated revenue per employee is $144891
  • ArcherDX's total funding is $95M.

Employee Data

  • ArcherDX has 230 Employees.
  • ArcherDX grew their employee count by 64% last year.
  • ArcherDX currently has 43 job openings.

Executive Contacts

NameTitle
Matt FranklinChief Business Officer
Steven DanielSenior Director, Applied Sciences and Business Development
Doug WendelSenior Director
Mike GomezDirector/Head of Quality
Todd DruleyChief Medical Officer
Blake AlexanderSales Director
Richard SjogrenVice President Operations
Abel LiconDirector of Software Research and Development
Aaron BerlinVice President of Bioinformatics and Commerical Software
Joshua StahlChief Scientific Officer and GM

What Is ArcherDX?

ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types. By combining novel enrichment chemistry, automated informatics and a user-friendly workflow, Archer products remove the bottlenecks associated with using next-gen sequencing in a translational setting.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

230

Number of Employees

$33.3M

Revenue (est)

43

Current Jobs

64%

Employee Growth %

$95M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
MBio Diagnostic...
$5.1M3535%
Mile High Labs
$26.2M181596%$100M
GlobeImmune
$5.1M350%
Isolate Extract...
$6.4M4433%
Front Range Bio...
$7.3M5067%
Inscripta
$15.8M10954%$134.2M
ArcherDX
$33.3M23064%$95M
Clovis Oncology
$95.4M54011%$763.3M
miRagen Therape...
$3.9M8619%public
Biodesix
$19.1M15619%$182M

ArcherDX News

09/08/2019 - Immune Repertoire Sequencing Market – Survey On Potential Players 2028 | Atreca, Inc., ArcherDX, Inc.

For example, Archer Immunoverse B Cell Receptor (BCR) was launched by ArcherDX, Inc in 2017 to examine human B cell repertoire.

05/15/2019 - ArcherDX Announces Close of $60M Financing to Advance ...

BOULDER, Colo., May 15, 2019 /PRNewswire/ -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough ...

03/05/2019 - ArcherDX Announces Expansion of Executive Leadership ...

BOULDER, Colo., March 5, 2019 /PRNewswire/ -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough ...

ArcherDX Funding

DateAmountRoundLead InvestorsReference
2018-03-21$35.0MABoulder Ventures, Ltd.Article

ArcherDX Acquisitions

DateCompany NameAmountNotesReference
2019-01-31Baby Genes, IncArticle